Mirabegron in the Management of Overactive Bladder Syndrome

References

• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26. doi:10.1007/s00192-009-0976-9
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178. doi:10.1002/nau.10052
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–1138. doi:10.1111/j.1464-410X.2010.09993.x
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455–463. doi:10.1111/j.1524-4733.2004.74008.x
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395. doi:10.1111/j.1464-410X.2008.07601.x
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108(9):1459–1471. doi:10.1111/j.1464-410X.2010.10013.x
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011;8(6):1603–1615. doi:10.1111/j.1743-6109.2011.02250.x
   PubMed Web of Science ®Google Scholar
• Kanai A, Andersson KE. Bladder afferent signaling: recent findings. J Urol. 2010;183(4):1288–1295. doi:10.1016/j.juro.2009.12.060
   Web of Science ®Google Scholar
• Andersson KE. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Ther Clin Risk Manag. 2013;9:161–170. doi:10.2147/TCRM.S33052
   PubMed Web of Science ®Google Scholar
• Imran M, Najmi AK, Tabrez S. Mirabegron for overactive bladder: a novel, first-in-class beta3-agonist therapy. Urol J. 2013;10(3):935–940.
   Web of Science ®Google Scholar
• Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology. 2003;62(5Suppl 2):28–37; discussion 40–2. doi:10.1016/j.urology.2003.09.050
   Web of Science ®Google Scholar
• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009;19(4):380–394. doi:10.1097/MOU.0b013e32832ce8a4
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–1774. doi:10.1111/j.1464-410X.2012.11023.x
   PubMed Web of Science ®Google Scholar
• Brubaker L, Fanning K, Goldberg EL, et al. Predictors of discontinuing overactive bladder medications. BJU Int. 2009;105(9):1283–1290. doi:10.1111/j.1464-410X.2009.09035.x
   Web of Science ®Google Scholar
• Sicras-Mainar A, Rejas J, Navarro-Artieda R, et al. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J. 2014;25(4):485–492. doi:10.1007/s00192-013-2250-4
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407. doi:10.1001/jamainternmed.2014.7663
   PubMed Web of Science ®Google Scholar
• Staskin DR, Zoltan E. Anticholinergics and central nervous system effects: are we confused? Rev Urol Fall. 2007;9(4):191–196.
   PubMedGoogle Scholar
• Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84(3):935–986. doi:10.1152/physrev.00038.2003
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4–6):473–481. doi:10.1007/s00210-008-0274-y
   PubMed Web of Science ®Google Scholar
• Takeda M, Obara K, Mizusawa T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther. 1999;288(3):1367–1373.
   PubMed Web of Science ®Google Scholar
• Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649–653. doi:10.1097/01.ju.0000067621.62736.7c
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9(4):433–448. doi:10.1517/17460441.2014.892923
   PubMed Web of Science ®Google Scholar
• Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323(1):202–209. doi:10.1124/jpet.107.125757
   PubMed Web of Science ®Google Scholar
• Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642–647. doi:10.1124/jpet.106.115840
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on intranet]. Approved drug products with therapeutic equivalence evaluations; 2020. Available from: https://www.fda.gov/media/136324/download. Accessed April 10, 2022.
   Google Scholar
• European Medicines Agency [homepage on the intranet]. Amsterdam: human medicine European public assessment report (EPAR): betmiga; 2012. Available from: https://www.ema.europa.eu/en. Accessed January 20, 2015.
   Google Scholar
• Astellas [press release]. FDA approves overactive bladder treatment myrbetriqTM (mirabegron) from Astellas; 2012. Available from: https://www.astellas.com/en/. Accessed March 13, 2015.
   Google Scholar
• Australian Therapeutic Goods Administration [homepage on the intranet]. Australian public assessment report: mirabegron; 2014. Available from: https://www.tga.gov.au. Accessed April 14, 2022.
   Google Scholar
• Limberg BJ, Andersson KE, Aura Kullmann F, Burmer G, de Groat WC, Rosenbaum JS. beta-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res. 2010;342(2):295–306. doi:10.1007/s00441-010-1053-x
   Web of Science ®Google Scholar
• Hatanaka T, Ukai M, Watanabe M, et al. Effect of mirabegron, a novel beta3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):71–78. doi:10.1007/s00210-012-0814-3
   PubMed Web of Science ®Google Scholar
• Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62(6):1165–1173. doi:10.1016/j.eururo.2012.08.056
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on intranet]. Center for drug evaluation and research pharmacology review(s); 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000PharmR.pdf. Accessed March 16, 2022.
   Google Scholar
• Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two Phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34(10):2144–2160. doi:10.1016/j.clinthera.2012.09.010
   PubMed Web of Science ®Google Scholar
• Iitsuka H, Tokuno T, Amada Y, et al. Pharmacokinetics of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. Clin Drug Investig. 2014;34(1):27–35. doi:10.1007/s40261-013-0146-1
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on intranet]. Center for drug evaluation and research clinical pharmacology and biopharmaceutics review(s); 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000ClinPharmR.pdf. Accessed March 22, 2022.
   Google Scholar
• Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815–824. doi:10.1124/dmd.111.043588
   PubMed Web of Science ®Google Scholar
• Iitsuka H, van Gelderen M, Katashima M, Takusagawa S, Sawamoto T. Pharmacokinetics of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder, in Healthy East Asian Subjects. Clin Ther. 2015;37(5):1031–1044. doi:10.1016/j.clinthera.2015.02.021
   PubMed Web of Science ®Google Scholar
• Chapple CR, Amarenco G, Lopez Aramburu MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32(8):1116–1122. doi:10.1002/nau.22373
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–1458. doi:10.1007/s00192-013-2042-x
   PubMed Web of Science ®Google Scholar
• Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706. doi:10.1038/clpt.2012.181
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian Phase 3 trial. Eur Urol. 2013;63(2):283–295. doi:10.1016/j.eururo.2012.10.016
   PubMed Web of Science ®Google Scholar
• Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urol. 2013;13:45. doi:10.1186/1471-2490-13-45
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–1395. doi:10.1016/j.juro.2012.10.017
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–320. doi:10.1016/j.urology.2013.02.077
   PubMed Web of Science ®Google Scholar
• Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32(4):621–638. doi:10.1185/03007995.2016.1149806
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Igawa Y, et al. Efficacy and safety of the selective beta3 -adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study. Low Urin Tract Symptoms. 2015;7(2):84–92. doi:10.1111/luts.12053
   PubMed Web of Science ®Google Scholar
• Matsukawa Y, Takai S, Funahashi Y, Yamamoto T, Gotoh M. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology. 2015;85(4):786–790. doi:10.1016/j.urology.2015.01.002
   PubMed Web of Science ®Google Scholar
• Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685–692. doi:10.1002/nau.22645
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–960. doi:10.1111/bju.12649
   PubMed Web of Science ®Google Scholar
• Takahashi S, Mishima Y, Kuroishi K, Ukai M. Efficacy of mirabegron, a beta3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol. 2022;29(1):7–15. doi:10.1111/iju.14700
   Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. doi:10.1016/j.eururo.2012.10.048
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Ikeda Y, Ohkawa S. Phase III study to assess long-term (52-week) safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in Japanese patients with overactive bladder. Low Urin Tract Symptoms. 2015. doi:10.1111/luts.12107
   Web of Science ®Google Scholar
• Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the beta3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Int J Clin Pract. 2014;68(8):972–985. doi:10.1111/ijcp.12433
   PubMed Web of Science ®Google Scholar
• Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular safety of beta3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311–323. doi:10.1016/j.eururo.2015.09.007
   PubMed Web of Science ®Google Scholar
• Batista JE, Kolbl H, Herschorn S, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7(4):167–179. doi:10.1177/1756287215589250
   PubMed Web of Science ®Google Scholar
• Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged >/=65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–220. doi:10.1016/j.eururo.2019.10.002
   PubMed Web of Science ®Google Scholar
• Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A. Safety and tolerability results from the PILLAR study: a Phase IV, double-blind, randomized, placebo-controlled study of mirabegron in patients >/= 65 years with overactive bladder-wet. Drugs Aging. 2020;37(9):665–676. doi:10.1007/s40266-020-00783-w
   Web of Science ®Google Scholar
• Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: moCA results from a Phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):109. doi:10.1186/s12877-020-1474-7
   PubMed Web of Science ®Google Scholar
• Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70(1):9–13. doi:10.1016/j.eururo.2016.02.007
   PubMed Web of Science ®Google Scholar
• Kim SC, Park M, Chae C, et al. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: a preliminary study. Investig Clin Urol. 2021;62(3):317–323. doi:10.4111/icu.20200380
   PubMed Web of Science ®Google Scholar
• Soliman MG, El-Abd S, El-Gamal OM, Raheem AA, Abou-Ramadan AR, El-Abd AS. Mirabegron versus solifenacin in children with overactive bladder: prospective randomized single-blind controlled trial. Urol Int. 2021;105(11–12):1011–1017. doi:10.1159/000515992
   PubMed Web of Science ®Google Scholar
• Baka-Ostrowska M, Bolong DT, Persu C, et al. Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: an open-label, phase 3, dose-titration study. Neurourol Urodyn. 2021;40(6):1490–1499. doi:10.1002/nau.24657
   Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Patient-reported outcomes with the beta -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourol Urodyn. 2015. doi:10.1002/nau.22844
   Web of Science ®Google Scholar
• Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Factors associated with improvements in patient-reported outcomes during mirabegron or antimuscarinic treatment of overactive bladder syndrome: a registry study (PERSPECTIVE). Adv Ther. 2019;36(8):1906–1921. doi:10.1007/s12325-019-00994-7
   PubMed Web of Science ®Google Scholar
• Castro-Diaz D, Chapple CR, Hakimi Z, et al. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. Qual Life Res. 2015;24(7):1719–1727. doi:10.1007/s11136-014-0904-4
   PubMed Web of Science ®Google Scholar
• Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid program. Value Health. 2005;8(4):495–505. doi:10.1111/j.1524-4733.2005.00041.x
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action; 2003. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed May 6, 2015.
   Google Scholar
• Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. 2009;65(3):309–314. doi:10.1007/s00228-008-0600-9
   Web of Science ®Google Scholar
• Wagg A, Foley S, Peters J, Scrine L. Persistence with mirabegron, a beta-3 adrenoceptor agonist, versus antimuscarinics in patients with over-active bladder: early UK experience. Eur Urol. 2015;14(2):e267–e267a.
   Google Scholar
• Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with mirabegron, a new beta-3 receptor agonist, versus antimuscarinics in overactive bladder: early experience in Canada. Value Health. 2014;17(7):A471. doi:10.1016/j.jval.2014.08.1336
   PubMed Web of Science ®Google Scholar
• Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–350. doi:10.5489/cuaj.3098
   PubMed Web of Science ®Google Scholar
• Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425–434. doi:10.1111/luts.12382
   PubMed Web of Science ®Google Scholar
• Duckett J, Balachandran A. Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. Int Urogynecol J. 2016. doi:10.1007/s00192-016-2945-4
   Web of Science ®Google Scholar
• Pindoria N, Malde S, Nowers J, Taylor C, Kelleher C, Sahai A. Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn. 2015. doi:10.1002/nau.22943
   Web of Science ®Google Scholar
• Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. 2018;29(2):273–283. doi:10.1007/s00192-017-3377-5
   PubMed Web of Science ®Google Scholar
• Herschorn S, Staskin D, Tu LM, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health Qual Life Outcomes. 2018;16(1):69. doi:10.1186/s12955-018-0892-0
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, Phase 2 study (Symphony). Eur Urol. 2015;67(3):577–588. doi:10.1016/j.eururo.2014.02.012
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2017;35(5):827–838. doi:10.1007/s00345-016-1908-1
   Web of Science ®Google Scholar
• Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–575. doi:10.1111/bju.13882
   PubMed Web of Science ®Google Scholar
• White WB, Chapple C, Gratzke C, et al. Cardiovascular safety of the beta3 -adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. J Clin Pharmacol. 2018;58(8):1084–1091. doi:10.1002/jcph.1107
   Web of Science ®Google Scholar
• Weber MA, Chapple CR, Gratzke C, et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Press Monit. 2018;23(3):153–163. doi:10.1097/MBP.0000000000000320
   PubMed Web of Science ®Google Scholar
• Mueller ER, van Maanen R, Chapple C, et al. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourol Urodyn. 2019;38(2):779–792. doi:10.1002/nau.23919
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre Phase 3b study (BESIDE). Eur Urol. 2016. doi:10.1016/j.eururo.2016.02.030
   Web of Science ®Google Scholar
• Drake MJ, MacDiarmid S, Chapple CR, et al. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). Int J Clin Pract. 2017;71(5). doi:10.1111/ijcp.12944
   Web of Science ®Google Scholar
• Gibson W, MacDiarmid S, Huang M, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study. Eur Urol Focus. 2017;3(6):629–638. doi:10.1016/j.euf.2017.08.008
   PubMedGoogle Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015;116(4):612–622. doi:10.1111/bju.13068
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study). Int J Urol. 2019;26(3):342–352. doi:10.1111/iju.13868
   Web of Science ®Google Scholar
• Takei M, Homma Y; Japanese Tolterodine Study G. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol. 2005;12(5):456–464. doi:10.1111/j.1442-2042.2005.01066.x
   Web of Science ®Google Scholar
• Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2008;15(11):986–991. doi:10.1111/j.1442-2042.2008.02152.x
   Web of Science ®Google Scholar
• Katoh T, Igawa Y, Yamaguchi O, Kato D, Hamada T, Kuroishi K. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a post hoc analysis from the Japanese MILAI II study. Low Urin Tract Symptoms. 2020;12(1):68–80. doi:10.1111/luts.12286
   Web of Science ®Google Scholar
• Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Arch Gerontol Geriatr. 2015;61(2):212–216. doi:10.1016/j.archger.2015.06.006
   PubMed Web of Science ®Google Scholar
• NICE. NICE technology appraisal guidance [TA290] Mirabegron for treating symptoms of overactive bladder; 2013. Available from: https://www.nice.org.uk/guidance/ta290. Accessed March 12, 2015.
   Google Scholar
• Aballea S, Maman K, Thokagevistk K, et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig. 2015;35(2):83–93. doi:10.1007/s40261-014-0240-z
   Web of Science ®Google Scholar
• Nazir J, Maman K, Neine ME, et al. Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom. Value Health. 2015;18(6):783–790. doi:10.1016/j.jval.2015.05.011
   Web of Science ®Google Scholar
• Nazir J, Posnett J, Walker A, Odeyemi IA, Hakimi Z, Garnham A. Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service. J Med Econ. 2015;18(5):390–397. doi:10.3111/13696998.2014.995300
   Web of Science ®Google Scholar